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Abstract
Background: Hearing Impairment (HI) can have genetic or environmental causes and in some cases, an interplay of
both. Genetic causes are difficult to determine as mutations in more than 90 genes have been shown recently to
be responsible for HI. Providing a genetic diagnostic test for HI is therefore a challenge especially for ethnic groups
where GJB2 mutations are shown to be rare.
Results: Here we show the design and implementation of an amplicon-based targeted sequencing panel that
allows the simultaneous sequencing of 87 HI genes. Mutations identified included known pathogenic mutations
and novel variants with unknown significance. The diagnostic rate of this panel is 28 % when only pathogenic
variants were reported. However, an additional 28 % harbored recurrent combinations of novel or rare single
nucleotide variants in the OTOF or PCDH15 genes. Such combinations were not identified in healthy individuals.
Conclusions: Targeted sequencing approach is a very useful strategy for the identification of mutations affecting
the HI genes because of its relatively fast turn-around time and cost effectiveness compared to whole-exome
sequencing. Further novel or rare variants could be identified by implementing a large-scale screening of HI using
our panel which will eventual lead to a higher diagnostic rate.
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Background
Hearing loss is a common disease found in many popu-
lations worldwide ast is estimated that at least 50 % of
prelingual hearing impairment (HI) is heritable either as
a phenotype in many syndromes or in a non-syndromic
fashion [1]. The heritability of HI follows all types of
Mendelian inheritance and can be passed down to sub-
sequent generations in autosomal/X-linked recessive or
dominant manner. The large number of genes required
for hearing causes such complexity in inheritance pat-
terns. Mutations in any one of such genes is sufficient
to cause various degrees of HI. Mutations in GJB2,
SLC26A4, MYO15A, OTOF, and CDH23 genes are the
most frequent causes of autosomal recessive HI at vary-
ing degrees [2]. On average, about 50 % of any given
cohort of autosomal recessive HI will have a pathogenic
mutation in the GJB2 gene [3–6]. However, the fre-
quency of HI-causing GJB2 gene mutations is
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population-dependent as it is most predominant HI
gene in Caucasians and rather rare in South East Asians
or Arab populations [7, 8].
The prevalence of the 35delG mutation in GJB2 gene
in Caucasians has allowed its use as a genetic screening
tool for early detection and diagnosis of HI in newborns.
However, such a test is not applicable in other ethnic
groups due to its rarity. In fact, since over 90 genes have
now been shown to be associated with HI, it is not
feasible to offer classical genetic testing for HI in many
populations. The advent of massively parallel sequen-
cing and whole-exome sequencing (WES) led to a
rapid increase in the rate of identifying the genetic de-
terminants of HI [9]. In order to achieve such aim,
whole-exome sequencing is applied to several mem-
bers of the affected family in order to identify the gen-
etic cause (s) of HI amongst hundreds of candidate
variants [10, 11]. Furthermore, WES is expensive and
time-consuming and it is not yet amenable for large-
scale screening of HI that will invariably include spor-
adic cases. Amplicon-based targeted sequencing is a
cost-effective tool to precede WES that will allow the
focused sequencing of relevant HI genes and improve
the diagnostic rate of such tests [12, 13].
In this study, we designed and validated a custom-
made amplicon-based targeted sequencing panel for
HI that allows the simultaneous sequencing of 87




Samples from 25 HI patients were collected following
the appropriate local ethical protocols and guidelines
from the Audiology clinic at King Abdulziz University
Hospital in Jeddah, Saudi Arabia or the Audiology de-
partment of the King Fahad General Hospital, Jeddah
Institute for Speech and Hearing (JISH) as well as Al-
Amal secondary school for the hearing impaired, Jeddah,
Saudi Arabia. All samples were selected according to the
diagnosis of bilateral severe-to-profound hearing impair-
ment as determined by audiologists in the study team.
The patients ages ranged from 4 to 22 years old. Control
samples were obtained from non-HI patients and aged
18–40 years old. DNA was extracted from peripheral
blood DNA using the standard protocol of the QIAGEN
Blood DNA Extraction kit. The study was approved by
the local ethical committee.
Targeted sequencing of deafness genes
Eighty-seven genes involved in HI were determined using
the Deafness Variation Database (http://deafnessvariation
database.org). The gene names were submitted for primer
design to the http://Ampliseq.com website were a targeted
sequencing panel was designed and manufactured by
Life Technologies. Barcoded Ampliseq libraries (2
pools) were prepared using the Ampliseq Library kit 2.0
from 10 ng of DNA (concentration determined using
the Qubit™ fluorometer). Templated spheres were pre-
pared using 100 pM of DNA from each library using
the Ion OneTouch 2.0 machine. Template-positive
spheres from the barcoded libraries were multiplexed
and loaded onto Ion chips 316 or 318 version 2.0 and
sequencing was performed using the Ion Sequencing
200 v2 kit from Life Technologies. Processing of the
Ion Torrent Personal Genome Machine (PGM) runs
was achieved with the Torrent Suite version 4.4.3. The
Coverage Analysis plugin was used to calculate cover-
age efficiency and read depth. The Ion Reporter v4.6
was used to identify and annotate variants.
DNA sequencing using the sanger method
Pathogenic and novel variants were confirmed by cus-
tom oligonucleotide primers designed to flank the
variant of interest in order to prepare PCR fragments
for sequencing. PCR was performed at optimal condi-
tion for each primer pair and products were purified
using ethanol precipitation. DNA sequencing was per-
formed using the BigDye v. 3.1 and analyzed on the
DNA Analyzer 3500 from Life Technologies. Addition-
ally, TaqMan® SNP genotyping assays, either custom-
designed or pre-made, were utilized in the validation
process or screening further cases.
Results
We have adopted the amplicon-based targeted sequen-
cing approach in order to develop a more efficient
method for the detection of mutations affecting the
deafness genes. In this approach, sequencing is limited
to the genes known or has been previously demonstrated
to play a role in causing HI. (Table 1) lists the genes in-
cluded in this panel obtained from the deafness variation
database (http://deafnessvariationdatabase.org).
Eighty-seven genes were selected and custom primers
were designed and manufactured through the ampliseq
portal (http://ampliseq.com). The design resulted in an
excellent coverage of 97.42 % generating 2697 amplicons
with a size range of 125–275 bp in two pools and gener-
ating 500.44 kb of DNA sequence. Identified variants
were confirmed by Sanger sequencing.
We have managed to screen 25 individuals affected
with HI using this approach. Additionally, we have
screened samples from 6 healthy volunteers with no his-
tory of HI as a control. Seven patients were found to
have pathogenic (according to clinvar database) muta-
tions affecting OTOF, MYO7A, TMC1 and GJB3 genes
(Table 2; Fig. 1). The homozygous c.2239C > A change in
the OTOF gene causes a premature termination of the
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protein at p. Glu747Ter. This mutation was identified in
a brother and sister suffering from severe to profound
HI. The homozygous IVS5 + 1G > A change in the
MYO7 gene is a mutation affecting the 5′ splice site and
was found in a brother and sister with severe to pro-
found HI in our screen. The p. Arg830His in MYO7A
gene is a very rare SNP (single nucleotide polymor-
phisms) with a reported minor allele frequency of
0.0001556 and classified as likely pathogenic by the
ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/).
This variant was identified in two of our patients with
severe to profound HI, albeit one of the patient harbored
the mutation in a heterozygous state thus could not
sufficiently account for the disease. The c.100C > T, p.
Arg34Ter variant in the TMC1 gene is a pathological
change according to ClinVar database. The c.100C > T,
p. Arg34Ter homozygous change in the TMC1 gene
causes the premature termination of the protein and
found only in one patient. The rs74315318 SNP is
c.547G > A change causing a p. Glu183Lys alteration in
Table 1 Genes included in our HI panel
Gene Coverage (%) Gene Coverage (%) Gene Coverage (%) Gene Coverage (%)
ACTG1 56.62 GIPC3 98.9 OTOA 97.82 TSPEAR 97.54
AIFM1 100 GJB2 100 OTOF 95.41 USH1C 97.21
ALMS1 99.25 GJB3 78.86 OTOG 98.3 USH1G 100
ATP2B2 100 GJB6 100 OTOGL 99.71 USH2A 98.87
CABP2 100 GPR98 99.42 P2RX2 80.21 WFS1 97.63
CACNA1D 100 GPSM2 100 PCDH15 98.27 WHRN 100
CATSPER2 100 GRHL2 100 PNPT1 97.07 MIR-182 100
CCDC50 100 GRXCR1 100 POU3F4 100 MIR-183 66
CDH23 99.55 HGF 99.4 POU4F3 100 MIR96 100
CEACAM16 94.39 ILDR1 95.7 PRPS1 100 DFNB59 100
CIB2 95.87 KCNQ1 86.04 PTPRQ 97.5 ESRRB 91.35
CLDN14 88.36 KCNQ4 87.25 RDX 100 TMPRSS3 100
CLPP 99.78 LARS2 98.63 SERPINB6 97.18
CLRN1 100 LHFPL5 100 SIX1 95.77
COCH 100 LOXHD1 99.72 SLC26A4 100
COL11A2 99.9 LRTOMT 100 SLC26A5 100
CRYL1 99.04 MARVELD2 100 SMAD4 100
CRYM 100 MSRB3 100 SMPX 100
DFNA5 100 MYH14 97.53 STRC 99.82
DIABLO 100 MYH9 98.11 TECTA 98.28
DIAPH1 98.49 MYO15 94.22 TJP2 98.17
DSPP 80.44 MYO1A 100 TMC1 96.54
ESPN 73.28 MYO3A 100 TMIE 79.84
EYA1 100 MYO6 100 TPRN 93.57
EYA4 100 MYO7A 98.72 TRIOBP 92.17
Table 2 Pathogenic mutations identified in our cohort
Position genotype gene transcript coding protein diagnosis
chr2:26700593 A/A OTOF NM_194248 c.2239G > T p. Glu747Ter Severe to profound
chr1:35250910 G/A GJB3 NM_001005752 c.547G > A p. Glu183Lys Severe to profound
chr11:76890902 A/A MYO7A NM_000260 c.2489G > A p. Arg830His Severe to profound
chr11:76867138 A/A MYO7A NM_000260 c.470 + 1G > A IVS5 + 1G > A Severe to profound
chr9:75309494 T/T TMC1 NM_138691 c.100C > T p. Arg34Ter Severe to profound
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the GJB3 gene. This variant is reported to be patho-
logical in an autosomal dominant fashion in the Clin-
Var database.
Although we could not identify additional known
pathogenic mutations in our cohort, we have identified 7
patients with a possible genetic aberration underlying
their HI. In these patients, two novel or rare SNVs were
identified affecting the same gene (Table 3). In particular,
in the OTOF and PCDH15 genes. The rare damaging
SNPs [minor allele frequency (MAF) of 0.001 and 0.006,
respectively] identified in combination in the PCDH15
gene were recurrent in 3 unrelated patients. Further-
more, we have designed custom-made TaqMan® SNP
genotyping assays targeting such mutations in order to
test whether the variants identified in this screen recur
in other unrelated patients. Interestingly, the combin-
ation identified by the panel was not found in 80 add-
itional HI patients or non-HI controls.
Discussion and conclusions
We have screened 25 HI patients using a custom-made
targeted sequencing panel to simultaneously screen 87
genes known to play a role in HI. Known pathogenic
mutations were identified in 7 patients which gives a
diagnostic rate of 28 %. The rs74315318 SNP is a
c.547G > A change causing a p. Glu183Lys alteration in
the GJB3 protein. This variant is reported to be
pathological in the ClinVar database [14] according to a
published report of its identification in Chinese families
with autosomal dominant hearing loss [15]. We have
also identified a homozygous c.2239C > A change in the
OTOF gene causing premature termination of protein at
p. Glu747Ter. This mutation was identified in a brother
and sister suffering from severe to profound HI. Al-
though not reported in the dbSNP, this variant was pre-
viously identified in a Libyan family [16]. The c.100C >
T, p. Arg34Ter homozygous change in the TMC1 gene
causes the premature termination of the protein and has
been previously reported in more than 23 probands with
sensorineural hearing loss [17–19]. We have identified
this variant in the homozygous state in one patient with
profound HI. The homozygous IVS5 + 1G > A change in
the MYO7A gene is a mutation affecting the 5′ splice
site and was found in a brother and sister with severe to
profound HI in our screen. This mutation was reported
only once previously in a Tunisian family enrolled in a
study of Usher 1B syndrome [20]. The p. Arg830His in
the MYO7A gene is a very rare SNP with a minor allele
frequency of 0.0001556 as reported by the exome aggre-
gation consortium (ExAC) data set [21]. This variant
was identified in two of our patients with profound HI.
Genetic factors underlying HI patients from Saudi
Arabia are not fully elucidated and therefore, other mu-
tations may play a role. For example, we have identified
Fig. 1 Sanger sequencing validation of the identified pathogenic variants (a) and the Integrated Genome Viewer view of the Ion Torrent BAM file
generated by the targeted sequencing using our custom-made HI panel demonstrating the detection of the p. Glu747Ter/c.2239C > A mutation
in the OTOF gene (b)
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in this study a C > T change in the sequence of the MIR-
96 microRNA which has been recently shown to play a
role in hearing [22]. This SNP is extremely rare and ac-
cording to the ExAC browser [21] carries a minor allele
frequency of 0.0001428. This mutation is also conserved
and lies close to the +57 T > C mutation recently shown
to cause autosomal dominant hearing loss in Italian
families by altering pre-miRNA processing [23]. This
variant was identified in a patient with severe to pro-
found hearing loss. In addition, we have identified a pa-
tient that harbored a rare rs369424114 variant in the
MYO7A gene. This variant has a minor allele frequency
of 0.0006688 and found predominantly in the south
Asian population [21].
An interesting observation in this cohort is the co-
existence of two damaging variants of PCDH15 gene in
3 unrelated patients. The reported MAF for the p.
Ala915Ser and the p. Ile817Thr variants is 0.001 and
0.006, respectively. Additionally, a novel OTOF gene
variant, p. Pro1463Ala, co-existed with another rare
OTOF variant, p. Arg49Trp, (MAF = 0.008) in one
patient. Another patient harbored the latter variant with
the rare p. Cys1251Gly variant (MAF = 0.009) affecting
the same gene. A third unrelated patient harbored the
rare p. Arg1157Gln variant in the OTOF gene (MAF =
0.001) as well as another rare variant, p. Arg19Gln, af-
fecting the same gene. The co-existence of such rare or
novel variants may reflect a new state of pathogenicity of
single nucleotide variants affecting the OTOF and
PCDH15 genes in our cohort.
In conclusion, our study shows that targeted sequen-
cing approach is a very useful strategy for the identifica-
tion of mutations affecting the HI genes. However,
further work is necessary to identify and characterize
novel variants in each ethnic group. Targeted sequencing
is relatively fast and cost effective compared to whole-
exome sequencing which renders possible the screening
of large cohorts of sporadic HI patients. Additionally,
targeted sequencing combined with next generation se-
quencing can be utilized as an aid for genetic counseling
of families affected with hearing impairment. Further-
more, such test can be applied as a premarital screening
Table 3 Novel or rare variants identified in our screen
Case Position ref genotype MAF gene protein coding SIFT (score) polyphen dbsnp transcript
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Benign (0) rs41288773 NM_194248.2
















































873 chr3:121712010 A A/G NA ILDR1 p. Val529Ala c.1586 T > C Tolerated
(1)
Benign (0.39) Novel NM_001199799.1
chr7:129414567 C C/T NA MIR96 rs370173345 NR_029512.1
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tool at a national level in order to significantly reduce
the burden of HI on the society.
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